Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Novo Nordisk has nominated its first candidate for treatment of liver-related cardiometabolic diseases under their collaboration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced Novo Nordisk A/S (“Novo”) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel therapies for the treatment of liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology.
“The past 12 months since closing our agreement with Novo have been extremely productive, with the identification and validation of multiple candidates under this highly collaborative relationship,” said Bob D. Brown, Executive Vice President and Head of Research and Development at Dicerna. “Tha